Tarsus Pharmaceuticals, Inc.

With $388.7M in cash and $88.7M in debt, TARS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$21.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -14.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.8M (2022) to $451.4M (2025), reflecting a 1648% increase over the period.

With a beta below 0.7, Tarsus Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TARS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.